Phase 1 Study of Belinostat (PXD-101) and Bortezomib (Velcade, PS-341) in Patients with Relapsed or Refractory Acute Leukemia and Myelodysplastic Syndrome

We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4, 8, and 11 every 21 days. QTc prolongation was the...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Leuk Lymphoma
Главные авторы: Holkova, Beata, Shafer, Danielle, Yazbeck, Victor, Dave, Sandeep, Bose, Prithviraj, Tombes, Mary Beth, Shrader, Ellen, Wan, Wen, Bandyopadhyay, Dipankar, Weir, Caryn, Collins, Elizabeth B., Garnett, Amanda, Kmieciak, Maciej, Roberts, John D., Garcia-Manero, Guillermo, Grant, Steven
Формат: Artigo
Язык:Inglês
Опубликовано: 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8106643/
https://ncbi.nlm.nih.gov/pubmed/33356689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1861270
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы